Craig C. Hopkinson - 02 Mar 2026 Form 4 Insider Report for Alkermes plc. (ALKS)

Reporting relationship: EVP R&D, Chief Medical Officer
Issuer ticker: ALKS
Reported as of: 02 Mar 2026
Net transaction value: -$267,485
SEC form: 4
Accepted by SEC: 04 Mar 2026, 20:16:25 UTC
Prior SEC filing: 27 Feb 2026
Next SEC filing: 01 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson

Key filing fact

Craig C. Hopkinson filed Form 4 for Alkermes plc. (ALKS) on 04 Mar 2026.

Key facts

This page summarizes Craig C. Hopkinson's Form 4 filing for Alkermes plc. (ALKS).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 04 Mar 2026, 20:16.

Change

Previous filing in this sequence was filed on 27 Feb 2026.
Current net transaction value: -$267,485.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001730048 Primary reporting owner

Hopkinson Craig C.

Relationship: EVP R&D, Chief Medical Officer
Address: 900 WINTER STREET, WALTHAM
Signature: /s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson
Signature date: 04 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALKS transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +5,000
Change %: +5.4%
Price: $19.34^*
Shares after: 98,389
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F1

ALKS transaction

Ordinary Shares

Sale

Transaction value: $267,485
Shares: -9,000
Change %: -9.1%
Price: $29.72
Shares after: 89,389
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALKS transaction Derivative

Employee Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -5,000
Change %: -19%
Price: $0.000000^*
Shares after: 21,356
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 5,000
Exercise price: $19.34
Footnotes: F1, F4

ALKS transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +83,037
Change %
Price: $0.000000^*
Shares after: 83,037
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 83,037
Exercise price: $30.25
Footnotes: F5

ALKS transaction Derivative

Restricted Stock Unit Award

Award

Transaction value
Shares: +38,568
Change %
Price: $0.000000^*
Shares after: 38,568
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 38,568
Exercise price
Footnotes: F6, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 7 footnotes

Footnote F1

This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

Footnote F2

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

Footnote F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.29 to $30.13. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

Footnote F4

These options are fully vested in accordance with their terms.

Footnote F5

Shares underlying the stock option vest and become exercisable in four equal annual installments, commencing on 3/2/2027.

Footnote F6

Each restricted stock unit represents a contingent right to receive one ordinary share.

Footnote F7

Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 3/2/2027.